Insulin giant Novo Nordisk (NYSE:NVO) has reportedly approached Global Blood Therapeutics (NSDQ:GBT) to discuss a possible takeover. The U.S. biotech is reviewing its options with an investment bank, according to Reuters, and there is no guarantee that it will enter formal negotiations with Novo Nordisk. Global Blood Therapeutics is developing GBT440, a once-daily, oral therapy to treat […]